CD274 and neoplasm: In spite of the existence of three current biomarkers (PD-L1 expression, microsatellite instability (MSI), or tumor mutational burden (TMB)) in clinical practice approved by the FDA for selecting patients receiving immunotherapy, all of them currently have weaknesses [16,35,36].